详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

Long Non-Coding RNAs: Potential Biomarkers and Targets for Hepatocellular Carcinoma Therapy and Diagnosis.

文献详情

资源类型：

Pubmed体系：

作者：

机构： [1]Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, Sichuan, China. [2]South Sichuan Institute of Translational Medicine, Luzhou, Sichuan, China. [3]Department of Oncology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China. [4]Department of Oncology and Hematology, Hospital (T.C.M) Affiliated to Southwest Medical University, Luzhou, Sichuan, China. [5]Department of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China. [6]Science and Technology Achievement Incubation Center, Kunming Medical University, Kunming, Yunnan, China

出处：

DOI：

摘要：

Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related death worldwide. Increasing studies showed that long non-coding RNAs (lncRNAs), a novel class of RNAs that are greater than 200 nucleotides in length but lack the ability to encode proteins, exert crucial roles in the occurrence and progression of HCC. LncRNAs promote the proliferation, migration, invasion, autophagy, and apoptosis of tumor cells by regulating downstream target gene expression and cancer-related signaling pathways. Meanwhile, lncRNA can be used as biomarkers to predict the efficacy of HCC treatment strategies, such as surgery, radiotherapy, chemotherapy, and immunotherapy, and as a potential individualized tool for HCC diagnosis and treatment. In this review, we overview up-to-date findings on lncRNAs as potential biomarkers for HCC surgery, radiotherapy, chemotherapy resistance, target therapy, and immunotherapy, and discuss the potential clinical application of lncRNA as tools for HCC diagnosis and treatment. © The author(s).

语种：

PubmedID：

中科院(CAS)分区：

出版当年[2021]版：

大类 | 2 区生物学

小类 | 2 区生化与分子生物学

最新[2023]版：

大类 | 2 区

生物学

小类 | 2 区生化与分子生物学

第一作者：

第一作者机构： [1]Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, Sichuan, China. [2]South Sichuan Institute of Translational Medicine, Luzhou, Sichuan, China.

共同第一作者：

通讯作者：

通讯机构： [1]Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, Sichuan, China. [2]South Sichuan Institute of Translational Medicine, Luzhou, Sichuan, China. [6]Science and Technology Achievement Incubation Center, Kunming Medical University, Kunming, Yunnan, China [*1]Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, Sichuan 646000, China [*2]Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, Sichuan 646000, China. [*3]Science and Technology Achievement Incubation Center, Kunming Medical University, Kunming, Yunnan 650500, China.

推荐引用方式(GB/T 7714)：

APA：

MLA：